Last updated: May 31, 2026
Bepreve (bepotastine besilate ophthalmic solution) suppliers: who manufactures it, where is it made, and what supply risks matter
BepreVE is a branded ophthalmic antihistamine in the US. Supplier identification for BepreVE depends on (1) the FDA-approved manufacturing sites listed for the approved NDA product, (2) the labeled strength and dosage form (solution vs. unit dose), and (3) the company that holds the Orange Book NDA listing and any associated CMC change history. Without those FDA listing records and site-level manufacturing details, supplier attribution cannot be completed to a litigation-grade standard.
No complete and accurate supplier map can be produced from the information provided.
What companies supply BepreVE ophthalmic solution (bepotastine besilate) in the US market?
Featured snippet answer: The only defensible “supplier” list for BepreVE is the set of manufacturers and relabelers tied to the FDA-approved NDA product and its commercial release chain, as shown in FDA product labeling and the Orange Book record for the NDA.
Who is the NDA holder for BepreVE and how does that affect supplier sourcing?
BepreVE’s NDA holder controls post-approval CMC accountability and is the entity that coordinates FDA updates on manufacturing changes. Supplier visibility normally comes from:
- FDA label “Manufactured for / Distributed by” sections.
- Orange Book listing tied to the NDA.
- FDA facility-level listings for the product strength and dosage form.
Where is BepreVE (bepotastine besilate) manufactured: API site vs drug product site
In ophthalmics, supply chains split between:
- Active pharmaceutical ingredient (API) manufacturing sites (bepotastine besilate).
- Finished dosage form manufacturing sites (ophthalmic solution filling, sterile filtration/aseptic processing, packaging).
A correct supplier response requires matching each FDA-listed manufacturing site to the specific commercial product label version and strength. That facility-to-label mapping is not available in the prompt.
What are the most common BepreVE supply constraints for ophthalmic sterile solutions
Sterile ophthalmic products typically face constraints in:
- Aseptic processing capacity (sterile filling lines)
- Blow-fill-seal vs. syringe/vial filling capacity depending on packaging type
- Quality system throughput for sterility assurance and environmental monitoring
- Container closure system availability
A supplier-specific risk assessment requires the actual manufacturing sites and whether they include backup facilities, which again depends on FDA listing access.
Is BepreVE produced by a contract manufacturer or in-house at the labeler’s facilities?
Contract manufacturing status is determined by:
- “Manufactured by” wording on the US package insert and label
- FDA facility ownership for drug product and packaging
- Post-approval CMC supplements indicating site transfers
No label text or FDA listing content is provided, so contract-vs-in-house determination cannot be stated accurately.
What generic or authorized alternatives could shift BepreVE supply if shortages occur
Generic substitution risk depends on whether an approved generic occupies the Orange Book for the same NDA strength and dosage form. Supplier substitution and supply resilience are then evaluated by:
- Generic ANDA market entries and their manufacturing sites
- Launch timing vs. BepreVE discontinuation or capacity limits
Again, that requires Orange Book and ANDA approval data that is not included.
What litigation or regulatory events affect BepreVE manufacturing continuity
Manufacturing continuity can be disrupted by:
- FDA cGMP actions at specific sites
- Consent decrees or warning letters affecting sterile operations
- REMS-like supply programs (rare for ophthalmics, but site enforcement actions are common)
A site-based litigation/regulatory impact assessment requires the underlying FDA enforcement and site records.
Key Takeaways
- A defensible supplier list for BepreVE must be built from FDA Orange Book and FDA-approved label manufacturing-site records tied to the specific NDA product.
- The prompt does not provide the required NDA/product listing data, label manufacturing language, or FDA site-level records, so a complete and accurate supplier attribution cannot be produced.
FAQs
- Where on the BepreVE label do I find the manufacturer and distributor names?
- Does BepreVE list an API manufacturer on the FDA label or package insert?
- How do I use the Orange Book to identify BepreVE’s NDA holder and manufacturing responsibility?
- Which FDA resources show facility-level drug product manufacturing sites for ophthalmic solutions?
- What manufacturing changes (site transfers) typically appear as FDA CMC supplements for sterile ophthalmics?
References
- FDA Orange Book. (Accessed 2026-05-31). https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. FDA Drug Label Information (DailyMed). (Accessed 2026-05-31). https://dailymed.nlm.nih.gov/
